ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    HCQ4Surfdefect : Hydroxychloroquine (HCQ) in pediatric ILD
Previous Study | Return to List | Next Study

Hydroxychloroquin (HCQ) in Pediatric Interstitial Lung Disease (ILD) (HCQ-chILD-EU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02615938
Recruitment Status : Recruiting
First Posted : November 26, 2015
Last Update Posted : April 23, 2018
Sponsor:
Information provided by (Responsible Party):
Matthias Griese, Ludwig-Maximilians - University of Munich

Brief Summary:
This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.

Condition or disease Intervention/treatment Phase
Interstitial Lung Disease Diffuse Parenchymal Lung Disease Children´s Interstitial Lung Disease Drug: Hydroxychloroquine sulfate Other: Placebo Phase 2

Detailed Description:
This study is an explorative, prospective, randomized, double-blind, placebo controlled investigation of hydroxychloroquine (HCQ) in pediatric ILD. The treatments are organized in START and STOP blocks, which can be initiated in sequence, as needed by the subjects. Each patient can participate in each block only once. In the START block subjects are randomized to parallel-groups, then the placebo group is switched to active drug. In the STOP block, subjects on HCQ are randomized into parallel-groups treated with placebo or HCQ to investigate the withdrawal of HCQ for assessment of its efficacy.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Hydroxychloroquine in Pediatric ILD: START Randomized Controlled in Parallel-group, Then Switch Placebo to Active Drug, and STOP Randomized Controlled in Parallel-Group to Evaluate the Efficacy and Safety of Hydroxychloroquine (HCQ)
Study Start Date : April 2015
Estimated Primary Completion Date : April 2024
Estimated Study Completion Date : April 2025


Arm Intervention/treatment
Experimental: Start HCQ block Verum
During trial: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
Drug: Hydroxychloroquine sulfate
Apply drug to modify lysosomal pH
Other Name: Quensyl

Placebo Comparator: Start HCQ block Placebo
At the beginning of the trial: Placebo for 4 weeks then Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
Other: Placebo
Apply Placebo not to modify lysosomal pH
Other Name: no other name

Experimental: Stop HCQ block Verum
Individual dose, usually Hydroxychloroquine Sulfate (HCQ, Quensyl) 6-10 mg/kg bw/d, p.o., one daily dose in the evening; the maximum daily dose is 400 mg. The dose, on which the patient is included into the trial, should be continued for 3 months. After therapy of 3 months the medication will be stopped. The patients will be followed up for additional 3 months.
Drug: Hydroxychloroquine sulfate
Apply drug to modify lysosomal pH
Other Name: Quensyl

Placebo Comparator: Stop HCQ block Placebo
Patients will receive Placebo for 3 months and will be followed up for additional 3 months.
Other: Placebo
Apply Placebo not to modify lysosomal pH
Other Name: no other name




Primary Outcome Measures :
  1. Change of Oxygenation [ Time Frame: Start HCQ block: 28 and 56 days; Stop HCQ block: 84 days ]

    Start HCQ block: relative Change Trial day 1 through day 28 and relative Change day 28 to day 56; Change active compound compared to Change Placebo.

    Stop HCQ block: Relative change trail day 1 through day 84: change active compound compared to change Placebo.



Secondary Outcome Measures :
  1. Change of Oxygen Saturation [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    (O2-sat, in room air) (only absolute, as relative already Primary outcome)

  2. Change of Respiratory rate [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    (RR, in room air) (relative and absolute)

  3. Change of Retraction, Coughing [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    (yes/no)

  4. Change of Lab values [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    (GOT, Creatinine, gGT, blood count, differential, LDH, potassium, steady state drug level)

  5. Change of Oxygen demand [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    in room air, on Os-supplement or O2 flow

  6. Change of QoL [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    (PedsQl™ generic and chILD specific module)

  7. Change of Health economics [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    specific questionaire

  8. Change of Overall survival [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    death or not

  9. Change of Weight to Height ratio [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    Weight measured in kg and Height measured in cm

  10. Cumulative amounts of Steroid equivalents [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    Clinical course of lung disease (since last visit): Healthy/ Sick-better/ Sick-same/ Sick-worse/ Patient died

  11. Change of x-ray [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    if x-ray were done

  12. Change of pO2, pCO2 [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    (capillary, in room air)

  13. Change of Pulmonary exacerbation [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    (since last visit)

  14. Change of Forced vital capacity [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    measured by spirometry or bodyplethysmography; If > 5y old (If a child ≤ 5 years is already able to perform the listed investigations (spirometry or bodyplethysmography), these should also be performed and documented at the discretion of the investigator.)

  15. Number of abnormal changes in Electrocardiographie (ECG) [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    measured on start and end of trial

  16. Change of 6 minute walking distance (6MWT) (in meter) [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    O2-saturation will be measured before and after 6MWT

  17. Change of Borg Scale [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    Measured after 6MWT

  18. Number of subjects with ophthalmologic abnormalities [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    Ophthalmologic review on start and end of trial

  19. Number of Treatment related advers events [ Time Frame: Start HCQ block: 28 days; Stop HCQ block: 84 days ]
    measured on each visit



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Patients should be clinically stable during baseline (between Visit 1 and 2) for inclusion into the study

    1. To determine this, attending physicians can use SpO2 in room air for patients on room air or on O2-supplement; the absolute difference on SpO2 is expected not to be ≥ 5% between Visit 1 and 2. For patients on respiratory support, the summary key parameters should not change ≥ 20% between Visit 1 and 2 and
    2. No major changes in other medications between Visit 1 and 2
  2. Mature newborn ≥ 37 weeks of gestation, age ≥ 3 wks and <2y or Infants and children (≥2y and < 18y) or Adults (≥18 and ≤30y) or Previously preterm (≤ 37 weeks of gestation) babies or children and adults of all ages if chILD genetically diagnosed (see inclusion criterion 3.)
  3. Diagnosis of chronic (≥ 3 wks of duration) diffuse parenchymal lung disease (DPLD = chILD), defined in at least one of the following ways:

    1. chILD genetically diagnosed Surfactant dysfunction disorders including patients with mutations in SFTPC, SFTPB, ABCA3, TTF1 (Nkx2-1), further extremely rare entities with specific mutations, for example in TBX4, NPC2, NPC1, NPB, COPA, LRBA and other genes. In this case, also previously preterm (≤ 37 weeks of gestation) babies or children and adults of all ages can be included into the study.
    2. chILD histologically diagnosed

      • Chronic pneumonitis of infancy (CPI)
      • Desquamative interstitial pneumonia (DIP)
      • Lipoid pneumonitis / Cholesterol pneumonia
      • Nonspecific interstitial pneumonia (NSIP)
      • PAP after the exclusion of mutations in GMCSF-Ra/b and GMCSF autoantibodies*
      • Usual interstitial pneumonia (UIP)
      • Follicular bronchitis/bronchiolitis/Lymphocytic interstitial pneumonia (LIP)
      • Storage disease with primary pulmonary involvement (e.g. Niemann Pick)
      • Hermansky-Pudlak Syndrome
      • Idiopathic pulmonary haemorrhage (haemosiderosis)*
      • Other histology diagnosing chILD, in particular combination of the above pattern, but not exclusively
  4. Start block: no HCQ treatment in the last 12 weeks Stop block: stable HCQ treatment for at least the last 12 weeks
  5. Ability of subject or/and legal representatives to understand character and individual consequences of clinical trial.
  6. Signed and dated informed consent of the subject (if subject has the ability) and the representatives (of underaged children) must be available before start of any specific trial procedures.

(*may be diagnosed in the absence of a lung biopsy by characteristic lung lavage cytology (PAS stain, Fe stain), CT pattern or autoantibodies (gliadin, endomysium; cANCA) and clinical course.)

Exclusion criteria:

Subjects presenting with any of the following criteria will not be included in the trial:

  • chILD primarily related to developmental disorders
  • chILD primarily related to growth abnormalities reflecting deficient alveolarisation
  • chILD related to chronic aspiration
  • chILD related to immunodeficiency
  • chILD related to abnormalities in lung vessel structure
  • chILD related to organ transplantation/organ rejection/GvHD
  • chILD related to recurrent infections
  • Acute severe infectious exacerbations
  • Known hypersensitivity to HCQ, or other ingredients of the tablets (lactose-monohydrate, povidone, maize starch, magnesium stearate, hypromellose, macrogol or titanium dioxide (E 171), silicon dioxide or mannitol), to sucrose-octaacetate or sodium saccharine.
  • Proven retinopathy or maculopathy
  • Glucose-6-phosphate-dehydrogenase deficiency resulting in favism or hemolytic anemia
  • Myasthenia gravis
  • Hematopoetic disorders
  • Pregnancy and lactation (Women with childbearing potential have to practice a medically accepted contraception during trial and till three months after the end of the treatment with HCQ, and a negative pregnancy test (serum or urine) should be existent on Visit 1, if girls of childbearing age and only if sexual relations are known or probable. It is at the discretion and responsibility of the attending physician to decide, whether a pregnancy test is necessary or not. Reliable contraception are systematic contraceptives (oral, implant, injection). Women that are sterile by surgery can participate in the trial. At the discretion of the investigator, sexual abstinence is also accepted as contraceptive method. Girls after menarche have to receive a counselling about birth control methods in presence of at least one parent, which has to be documented in the patient notes.
  • Participation in other clinical trials during the present clinical trial or not beyond the time of 4 half-lives of the medication used, at least one week.
  • Hereditary galactose intolerance, lactase deficiency or glucose-galactose- malabsorption
  • Renal insufficiency at screening, defined as glomerular filtration rate (GFR)

    • < 40 mL/min/1.73 m2 in patients age 3 to 8 weeks
    • < 60 mL/min/1.73 m2 in patients ≥ 8 weeks of age (KDIGO guideline 2012, K/DOQI guideline 2002)
  • Liver disease, gastrointestinal disorder, haematological disorder, epilepsy or other neurological disorder, psoriasis, porphyria at the discretion of the treating physician
  • Simultaneous prescription of other potentially nephrotoxic or hepatotoxic medication at the discretion of the treating physician

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02615938


Contacts
Contact: Matthias Griese, Prof., MD +49 (0) 89 4400 ext 57870 Matthias.Griese@med.uni-muenchen.de
Contact: Elias Seidl, MD +49 (0) 89 4400 ext 57871 Elias.Seidl@med.uni-muenchen.de

Locations
Germany
Universitätsklinik für Kinder- und Jugendmedizin Tübingen Recruiting
Tübingen, Baden-Württemberg, Germany, 72076
Contact: Winfried Baden, MD    +49 (0) 7071 29 ext 84712    winfried.baden@med.uni-tuebingen.de   
Klinikum der Universität München, Haunersches Kinderspital Recruiting
München, Bayern, Germany, 80337
Contact: Matthias Griese, Prof., MD    +49 (0) 89 4400 ext 57870    matthias.griese@med.uni-muenchen.de   
Contact: Elias Seidl, MD    +49 (0) 89 4400 ext 57870      
Universitätsklinikum Frankfurt, Pneumologie, Allergologie, Mukoviszidose Recruiting
Frankfurt, Hessen, Germany, 60590
Contact: Stefan Zielen, Prof., MD    +49 (0) 69 6301 ext 83063    stefan.zielen@kgu.de   
Justus-Liebig-Universität, Allgemeine Pädiatrie u. Neonatologie Recruiting
Gießen, Hessen, Germany, 35385
Contact: Lutz Nährlich, MD    +49 (0) 641 9855 ext 7620    lutz.naehrlich@paediat.med.uni-giessen.de   
Medizinische Hochschule Hannover Recruiting
Hannover, Niedersachsen, Germany, 30625
Contact: Nicolaus Schwerk, MD    +49 (0) 511 5329 ext 138    schwerk.nicolaus@mh-hannover.de   
Contact: Martin Wetzke, MD    +49 (0) 511 5329 ext 138      
St. Joseph- und St. Elisabeth Hospital gGmbH Recruiting
Bochum, Nordrhein-Westfalen, Germany, 44791
Contact: Cordula Koerner-Rettberg, MD    +49 (0) 234 509 ext 6605    Cordula.Koerner-Rettberg@klinikum-bochum.de   
Uniklinikum Essen, Pädiatrische Pneumologie Recruiting
Essen, Nordrhein-Westfalen, Germany, 45122
Contact: Florian Stehling, MD    +49 (0) 201 723 ext 3350    florian.stehling@uk-essen.de   
Contact: Uwe Mellies, PD, MD    +49 (0) 201 723 ext 3350      
Klinik u. Poliklinik für Kinder- u. Jugendmedizin der Universität Leipzig Recruiting
Leipzig, Sachsen, Germany, 04103
Contact: Freerk Prenzel, MD    +49 (0) 341 9726 ext 838    freerk.prenzel@medizin.uni-leipzig.de   
Charité Berlin, Klinik für Pädiatrie Not yet recruiting
Berlin, Germany, 13353
Contact: Anne Mehl, MD    +49 (0) 30 4505 ext 66552    anne.mehl@charite.de   
Contact: Susanne G. Lau, Prof., MD    +49 (0) 30 4505 ext 66552      
Sponsors and Collaborators
Matthias Griese
Investigators
Study Director: Matthias Griese, Prof., MD Pediatric Pneumology, Ludwig-Maximilians-University Munich
Principal Investigator: Elias Seidl, MD Pediatric Pneumology, Ludwig-Maximilians University Munich

Responsible Party: Matthias Griese, Prof. Dr. med., Ludwig-Maximilians - University of Munich
ClinicalTrials.gov Identifier: NCT02615938     History of Changes
Other Study ID Numbers: EudratCT:2013-003714-40
First Posted: November 26, 2015    Key Record Dates
Last Update Posted: April 23, 2018
Last Verified: March 2018

Additional relevant MeSH terms:
Hydroxychloroquine
Lung Diseases
Lung Diseases, Interstitial
Respiratory Tract Diseases
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents